200 related articles for article (PubMed ID: 29802984)
21. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
22. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
23. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
25. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
26. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
Antimicrob Agents Chemother; 2010 Jul; 54(7):2901-9. PubMed ID: 20439609
[TBL] [Abstract][Full Text] [Related]
27. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
Cobb DA; Smith N; Deodhar S; Bade AN; Gautam N; Shetty BLD; McMillan J; Alnouti Y; Cohen SM; Gendelman HE; Edagwa B
Nat Commun; 2021 Sep; 12(1):5458. PubMed ID: 34531390
[TBL] [Abstract][Full Text] [Related]
28. Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche.
Carballo-Dieguez A; Giguere R; Lentz C; Dolezal C; Fuchs EJ; Hendrix CW
AIDS Behav; 2019 Jun; 23(6):1484-1493. PubMed ID: 30415431
[TBL] [Abstract][Full Text] [Related]
29. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
31. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
Cox S; Margot N; Callebaut C
J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
[TBL] [Abstract][Full Text] [Related]
32. A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
Peterson S; Ibrahim M; Anderson PL; Moore CM; MaWhinney S
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):655-669. PubMed ID: 34013454
[TBL] [Abstract][Full Text] [Related]
33. Repeated rectal application of a hyperosmolar lubricant is associated with microbiota shifts but does not affect PrEP drug concentrations: results from a randomized trial in men who have sex with men.
Haaland RE; Fountain J; Hu Y; Holder A; Dinh C; Hall L; Pescatore NA; Heeke S; Hart CE; Xu J; Hu YJ; Kelley CF
J Int AIDS Soc; 2018 Oct; 21(10):e25199. PubMed ID: 30378274
[TBL] [Abstract][Full Text] [Related]
34. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
35. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
[TBL] [Abstract][Full Text] [Related]
36. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
37. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
38. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
39. A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035).
Bauermeister JA; Dominguez Islas C; Jiao Y; Tingler R; Brown E; Zemanek J; Giguere R; Balan I; Johnson S; Macagna N; Lucas J; Rose M; Jacobson C; Collins C; Livant E; Singh D; Ho K; Hoesley C; Liu A; Kayange N; Palanee-Phillips T; Chariyalertsak S; Gonzales P; Piper J;
PLoS One; 2023; 18(4):e0284339. PubMed ID: 37043527
[TBL] [Abstract][Full Text] [Related]
40. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]